My usual effervescence and optimism disappeared momentarily when I learned last week that the Australian Therapeutic Goods Administration (TGA) has approved the use of donanemab in Australia. Evidence is weak for benefits, but high for serious side effects, some even causing death. It is only for people in the early stages of Alzheimer’s disease. And…